Gapping up
News:
- KKR +8.2% (to join S&P 500)
- ZYME +7.9% (receives NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer in China)
- PROK +7.2% (Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates)
- DO +7% (Diamond Offshore to be acquired by Noble Corp (NE))
- CRWD +5.9% (to join S&P 500)
- STTK +5.3% (FDA has granted orphan drug designation to lead clinical candidate SL-172154 for the treatment of AML)
- DTI +4.8% (announces expected addition to Russell US Indexes)
- SOPH +3.8% (files for 200,000 ordinary share offering by selling shareholder)
- CCCC +3% (appoints Ron Cooper as Chairman of the Board of Directors)
- GDDY +2.8% (to join S&P 500)
- CSV +2.3% ( CFO to resign, effective July 1)
- DKNG +1.9% (files mixed shelf securities offering)
- SWTX +1.9% (receives notice of termination of collaboration and license agreement with GSK)
- MRNA +1.5% (announces positive phase 3 data for combination vaccine against influenza and COVID-19)
- FDMT +1.2% (Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting)
- OXY +1.2% (10% owner Berkshire Hathaway's (BRK.A) Warren Buffett bought 2,565,477 shares worth approx. $153.3 mln)
- CANF +1.2% (received an approval from the Institutional Review Board of Rabin Medical Center)
Analyst comments:
- DNUT +4% (upgraded to Buy from Hold at Truist)
- PLNT +3.2% (upgraded to Buy from Hold at Jefferies)
- LAD +1.9% (upgraded to Overweight from Neutral at JP Morgan)
- WMT +1.4% (upgraded to Overweight from Neutral at JP Morgan)